{
  "first_published_at": "2012-06-22", 
  "original_url": "http://www.mhra.gov.uk/Safetyinformation/DrugSafetyUpdate/CON155758", 
  "title": "Febuxostat (Adenuric▼): stop treatment if signs or symptoms of serious hypersensitivity (eg, serious skin reactions or systemic hypersensitivity) occur ", 
  "tags": "{\"parsed_therapeutic\": [\"rheumatology\"], \"Audience:\": [\"Primary care\", \"Secondary care\"], \"Therapeutic area:\": [\"Rheumatology\"]}", 
  "_document_number": 110, 
  "label": null, 
  "icon": "http://www.mhra.gov.uk/home/images/MHRALook/img/dsu/adverse_icon.png", 
  "therapeutic_area": [
    "rheumatology"
  ], 
  "raw_html": "<div id=\"dsuArticleContent\">\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t\t<h1><a name=\"maincontent\" id=\"maincontent\"></a>Febuxostat (Adenuric&#9660;): stop treatment if signs or symptoms of serious hypersensitivity (eg, serious skin reactions or systemic hypersensitivity) occur </h1>\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<span class=\"ref\">Article date: June 2012</span> \r\n\t\t\t\t\t\t\t\t<!--SS_BEGIN_ELEMENT(region1_element21)-->\r\n\t\t\t\t\t\t\t\t<!---->\r\n\t\t\t\t\t\t\t\t<!--SS_END_ELEMENT(region1_element21)-->\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<!--SS_BEGIN_ELEMENT(region1_element22)-->\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<!--SS_END_ELEMENT(region1_element22)-->\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<div id=\"dsuSynopsis\" class=\"yellow\">\r\n\t\t\t\t\t\t\t\t\t<div class=\"dsuArticlePadding\">\r\n\t\t\t\t\t\t\t\t\t<span id=\"dsuSynopsisTitle\"><b>Summary</b></span>\t\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t\t<br>There have been rare but serious reports of hypersensitivity reactions, including Stevens-Johnson syndrome and acute anaphylactic shock, with febuxostat (Adenuric&#9660;). Febuxostat must be stopped immediately if hypersensitivity occurs, and must not be re-started in patients who have ever developed a hypersensitivity reaction to febuxostat.<br>\t\r\n\t\t\t\t\t\t\t\t\t</div>         \t\t\r\n\t\t\t\t\t\t\t\t\t<div id=\"dsuSynopsisCut\">\r\n\t\t\t\t\t\t\t\t\t</div>\r\n\t\t\t\t\t\t\t\t</div>\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<!--SS_BEGIN_ELEMENT(region1_element13)-->\r\n\t\t\t\t\t\t\t\t<!--<p>Febuxostat (Adenuric&#9660;) is a non-purine, xanthine oxidase inhibitor licensed for the treatment of chronic hyperuricaemia in adults, in whom urate deposition has already occurred (including a history, or presence of, tophus and/or gouty arthritis).</p>\n\n<p>Since its launch in 2009 there have been rare but serious reports of hypersensitivity reactions to febuxostat, some associated with systemic symptoms. These have included rare reports of Stevens-Johnson syndrome and acute anaphylactic shock (frequency: equal to or more than 1/10 000 to less than 1/1000).</p>\n\n<p>In most cases, the reactions occurred during the first month of treatment. Some, but not all, of the patients experiencing hypersensitivity reactions to febuxostat were reported to have a prior history of hypersensitivity to allopurinol and/or renal disease&#60;</p>\n\n<p><a target=\"_blank\" href=\"http://www.mhra.gov.uk/Safetyinformation/Safetywarningsalertsandrecalls/Safetywarningsandmessagesformedicines/Monthlylistsofinformationforhealthcareprofessionalsonthesafetyofmedicines/CON152832\">A letter on this safety issue</a> was sent to healthcare professionals in May 2012 and the product information has been updated with relevant warnings.</p>\n\n<div class=\"dull_highlight\">\n<p><strong>Advice for healthcare professionals:</strong></p>\n\n<ul>\n<li>Febuxostat treatment should be stopped immediately if signs or symptoms of serious hypersensitivity reactions occur &#8211; early withdrawal is associated with a better prognosis</li>\n\n<li>If a patient has ever developed a hypersensitivity reaction with febuxostat, including Stevens-Johnson syndrome, febuxostat must not be re-started at any time</li>\n\n<li>Most cases of hypersensitivity to febuxostat occur during the first month of treatment</li>\n\n<li>Patients should be advised of signs and symptoms of severe hypersensitivity or Stevens-Johnson syndrome. These include: infiltrated maculopapular eruption; generalised or exfoliative rashes; skin lesions; facial oedema, fever, haematologic abnormalities such as thrombocytopenia, a single or multiple organ involvement (liver and kidney including tubulointerstitial nephritis), progressive skin rashes associated with blisters or mucosal lesions and eye irritation</li>\n\n<li>A prior history of hypersensitivity to allopurinol and/or renal disease may indicate potential hypersensitivity to febuxostat<br />\n</li>\n</ul>\n</div>\n\n<p><strong>Further information:</strong></p>\n\n<p><a target=\"_blank\" href=\" http://www.mhra.gov.uk/Safetyinformation/Safetywarningsalertsandrecalls/Safetywarningsandmessagesformedicines/Monthlylistsofinformationforhealthcareprofessionalsonthesafetyofmedicines/CON152832\">Letter to healthcare professionals sent in May 2012</a></p>\n\n<p>BNF section 10.1: <a target=\"_blank\" href=\"http://www.medicinescomplete.com/mc/bnf/current/204954.htm\">Drugs used in rheumatic diseases and gout</a></p>\n\n<p><em>Article citation: Drug Safety Update June 2012, vol 5 issue 11: A3</em></p>-->\r\n\t\t\t\t\t\t\t\t<!--SS_END_ELEMENT(region1_element13)-->\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<!-- SS_BEGIN_SNIPPET(fragment7,1)-->\r\n\t\t\t\t\t\t\t\t<!-- call include to dynamically insert alt attributes into image tags within a wysiwyg element -->\r\n<!-- get a reference to the wysiwyg content -->\r\n<!-- parse hyperlinked images -->\r\n<!-- parse word documents -->\r\n<!-- parse powerpoint documents -->\r\n<!-- parse excel documents -->\r\n<!-- parse pdf documents -->\r\n<!-- parse links to the site -->\r\n<!-- remove all hardlinks to cms -->\r\n<!-- replace /stellent/ with current webroot -->\r\n<!-- parse hyperlinked images -->\r\n<!-- parse word documents -->\r\n<!-- parse powerpoint documents -->\r\n<!-- parse excel documents -->\r\n<!-- parse pdf documents -->\r\n<!-- parse links to the site -->\r\n<!-- remove all hardlinks to cms -->\r\n<!-- replace /stellent/ with current webroot -->\r\n\t<p>Febuxostat (Adenuric&#9660;) is a non-purine, xanthine oxidase inhibitor licensed for the treatment of chronic hyperuricaemia in adults, in whom urate deposition has already occurred (including a history, or presence of, tophus and/or gouty arthritis).</p>\n\n<p>Since its launch in 2009 there have been rare but serious reports of hypersensitivity reactions to febuxostat, some associated with systemic symptoms. These have included rare reports of Stevens-Johnson syndrome and acute anaphylactic shock (frequency: equal to or more than 1/10 000 to less than 1/1000).</p>\n\n<p>In most cases, the reactions occurred during the first month of treatment. Some, but not all, of the patients experiencing hypersensitivity reactions to febuxostat were reported to have a prior history of hypersensitivity to allopurinol and/or renal disease&lt;</p>\n\n<p><a target=\"_blank\" href=\"http://www.mhra.gov.uk/Safetyinformation/Safetywarningsalertsandrecalls/Safetywarningsandmessagesformedicines/Monthlylistsofinformationforhealthcareprofessionalsonthesafetyofmedicines/CON152832\">A letter on this safety issue</a> was sent to healthcare professionals in May 2012 and the product information has been updated with relevant warnings.</p>\n\n<div class=\"dull_highlight\">\n<p><strong>Advice for healthcare professionals:</strong></p>\n\n<ul>\n<li>Febuxostat treatment should be stopped immediately if signs or symptoms of serious hypersensitivity reactions occur &#8211; early withdrawal is associated with a better prognosis</li>\n\n<li>If a patient has ever developed a hypersensitivity reaction with febuxostat, including Stevens-Johnson syndrome, febuxostat must not be re-started at any time</li>\n\n<li>Most cases of hypersensitivity to febuxostat occur during the first month of treatment</li>\n\n<li>Patients should be advised of signs and symptoms of severe hypersensitivity or Stevens-Johnson syndrome. These include: infiltrated maculopapular eruption; generalised or exfoliative rashes; skin lesions; facial oedema, fever, haematologic abnormalities such as thrombocytopenia, a single or multiple organ involvement (liver and kidney including tubulointerstitial nephritis), progressive skin rashes associated with blisters or mucosal lesions and eye irritation</li>\n\n<li>A prior history of hypersensitivity to allopurinol and/or renal disease may indicate potential hypersensitivity to febuxostat<br>\n</li>\n</ul>\n</div>\n\n<p><strong>Further information:</strong></p>\n\n<p><a target=\"_blank\" href=\"http://www.mhra.gov.uk/Safetyinformation/Safetywarningsalertsandrecalls/Safetywarningsandmessagesformedicines/Monthlylistsofinformationforhealthcareprofessionalsonthesafetyofmedicines/CON152832\">Letter to healthcare professionals sent in May 2012</a></p>\n\n<p>BNF section 10.1: <a target=\"_blank\" href=\"http://www.medicinescomplete.com/mc/bnf/current/204954.htm\">Drugs used in rheumatic diseases and gout</a></p>\n\n<p><em>Article citation: Drug Safety Update June 2012, vol 5 issue 11: A3</em></p>\r\n\t\t\t\r\n\t\t\t\t\t\t\t\t<!-- SS_END_SNIPPET(fragment7,1)-->\r\n\t\t\t\t\t\t\t</div>\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t", 
  "date_of_article": "2012-06-01", 
  "date_last_modified": "2012-06-21", 
  "_assets": [], 
  "_item_id": 110, 
  "summary": "There have been rare but serious reports of hypersensitivity reactions, including Stevens-Johnson syndrome and acute anaphylactic shock, with febuxostat (Adenuric▼). Febuxostat must be stopped immediately if hypersensitivity occurs, and must not be re-started in patients who have ever developed a hypersensitivity reaction to febuxostat.", 
  "body": "Article date: June 2012\n\nFebuxostat (Adenuric▼) is a non-purine, xanthine oxidase inhibitor licensed for the treatment of chronic hyperuricaemia in adults, in whom urate deposition has already occurred (including a history, or presence of, tophus and/or gouty arthritis).\n\nSince its launch in 2009 there have been rare but serious reports of hypersensitivity reactions to febuxostat, some associated with systemic symptoms. These have included rare reports of Stevens-Johnson syndrome and acute anaphylactic shock (frequency: equal to or more than 1/10 000 to less than 1/1000).\n\nIn most cases, the reactions occurred during the first month of treatment. Some, but not all, of the patients experiencing hypersensitivity reactions to febuxostat were reported to have a prior history of hypersensitivity to allopurinol and/or renal disease<\n\n[A letter on this safety issue](http://www.mhra.gov.uk/Safetyinformation/Safetywarningsalertsandrecalls/Safetywarningsandmessagesformedicines/Monthlylistsofinformationforhealthcareprofessionalsonthesafetyofmedicines/CON152832) was sent to healthcare professionals in May 2012 and the product information has been updated with relevant warnings.\n\nAdvice for healthcare professionals:  \n  \n  * Febuxostat treatment should be stopped immediately if signs or symptoms of serious hypersensitivity reactions occur – early withdrawal is associated with a better prognosis  \n  * If a patient has ever developed a hypersensitivity reaction with febuxostat, including Stevens-Johnson syndrome, febuxostat must not be re-started at any time  \n  * Most cases of hypersensitivity to febuxostat occur during the first month of treatment  \n  * Patients should be advised of signs and symptoms of severe hypersensitivity or Stevens-Johnson syndrome. These include: infiltrated maculopapular eruption; generalised or exfoliative rashes; skin lesions; facial oedema, fever, haematologic abnormalities such as thrombocytopenia, a single or multiple organ involvement (liver and kidney including tubulointerstitial nephritis), progressive skin rashes associated with blisters or mucosal lesions and eye irritation  \n  * A prior history of hypersensitivity to allopurinol and/or renal disease may indicate potential hypersensitivity to febuxostat  \n  \n  \nFurther information:\n\n[Letter to healthcare professionals sent in May 2012](http://www.mhra.gov.uk/Safetyinformation/Safetywarningsalertsandrecalls/Safetywarningsandmessagesformedicines/Monthlylistsofinformationforhealthcareprofessionalsonthesafetyofmedicines/CON152832)\n\nBNF section 10.1: [Drugs used in rheumatic diseases and gout](http://www.medicinescomplete.com/mc/bnf/current/204954.htm)\n\nArticle citation: Drug Safety Update June 2012, vol 5 issue 11: A3\n"
}